Thrombopoietin Receptor Agonists [MoA]

Known as: Thrombopoietin Receptor Agonists 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Background: Data on the safety and efficacy of thrombopoietin receptor agonists (TRAs) in pregnancy are very limited, although… (More)
Is this relevant?
2016
2016
BACKGROUND The aim of this study was to evaluate the treatment reality for outpatients with immune thrombocytopenia (ITP) managed… (More)
  • table 1
  • figure 1
Is this relevant?
Review
2016
Review
2016
Immune thrombocytopenia (ITP) is an acquired hemorrhagic condition characterized by the accelerated clearance of platelets caused… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2016
2016
BACKGROUND Eltrombopag and romiplostim are thrombopoietin receptor agonists (TPOs) that have been increasingly used for the… (More)
  • table 3
  • table 1
  • table 2
  • figure 1
  • table 4
Is this relevant?
2016
2016
Very few data exist on the management of adult patients diagnosed with primary immune thrombocytopenia (ITP). The objectives of… (More)
  • table 1
  • table 3
  • table 4
  • table 5
Is this relevant?
2013
2013
BACKGROUND Thrombopoietin receptor agonists (TRAs) are effective treatments for immune thrombocytopenia (ITP). However… (More)
Is this relevant?
2013
2013
BACKGROUND AND OBJECTIVES Thrombopoietin receptor agonists (TPOra) are the only treatments for immune thrombocytopenia (ITP) for… (More)
  • figure 1
  • table 2
  • table 3
  • figure 2
  • figure 3
Is this relevant?
2013
2013
Thrombopoietin receptor agonists (TRAs) offer new opportunities for the treatment of chronic immune thrombocytopenia (ITP… (More)
  • figure 1
Is this relevant?
2012
2012
AIM: Thrombopoietin receptor agonists (Tpo RA) increase platelet counts in the majority of chronic autoimmune thrombocytopenia… (More)
  • table 1
  • table 2
  • figure 2
Is this relevant?